PMID- 22147202
OWN - NLM
STAT- MEDLINE
DCOM- 20120523
LR  - 20151119
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Linking)
VI  - 14
IP  - 2
DP  - 2012 Feb
TI  - Effects of the long-term administration of nebivolol on the clinical symptoms, 
      exercise capacity, and left ventricular function of patients with diastolic 
      dysfunction: results of the ELANDD study.
PG  - 219-25
LID - 10.1093/eurjhf/hfr161 [doi]
AB  - AIMS: We hypothesized that nebivolol, a beta-blocker with nitric oxide-releasing 
      properties, could favourably affect exercise capacity in patients with heart 
      failure and preserved left ventricular ejection fraction (HFPEF). METHODS AND 
      RESULTS: A total of 116 subjects with HFPEF, in New York Heart Association (NYHA) 
      functional class II-III, with left ventricular ejection fraction (LVEF) >45%, and 
      with echo-Doppler signs of LV diastolic dysfunction, were randomized to 6 months 
      treatment with nebivolol or placebo, following a double-blind, parallel group 
      design. The primary endpoint of the study was the change in 6 min walk test 
      distance (6MWTD) after 6 months. Nebivolol did not improve 6MWTD (from 420 +/- 143 
      to 428 +/- 141 m with nebivolol vs. from 412 +/- 123 to 446 +/- 119 m with placebo, P = 
      0.004 for interaction) compared with placebo, and the peak oxygen uptake also 
      remained unchanged (peakVO(2); from 17.02 +/- 4.79 to 16.32 +/- 3.76 mL/kg/min with 
      nebivolol vs. from 17.79 +/- 5.96 to 18.59 +/- 5.64 mL/kg/min with placebo, P = 0.63 
      for interaction). Resting and peak blood pressure and heart rate decreased with 
      nebivolol. A significant correlation was found between the change in peak 
      exercise heart rate and that in peakVO(2) (r = 0.391; P = 0.003) for the 
      nebivolol group. Quality of life, assessed using the Minnesota Living with Heart 
      Failure Questionnaire, and NYHA classification improved to a similar extent in 
      both groups, whereas N-terminal pro brain natriuretic peptide (NT-pro BNP) plasma 
      levels remained unchanged. CONCLUSIONS: Compared with placebo, 6 months treatment 
      with nebivolol did not improve exercise capacity in patients with HFPEF. Its 
      negative chronotropic effect may have contributed to this result.
FAU - Conraads, Viviane M
AU  - Conraads VM
AD  - Department of Cardiology, Antwerp University Hospital, Edegem, Belgium, 
      University of Antwerp, Antwerp, Belgium.
FAU - Metra, Marco
AU  - Metra M
FAU - Kamp, Otto
AU  - Kamp O
FAU - De Keulenaer, Gilles W
AU  - De Keulenaer GW
FAU - Pieske, Burkert
AU  - Pieske B
FAU - Zamorano, Jose
AU  - Zamorano J
FAU - Vardas, Panos E
AU  - Vardas PE
FAU - Bohm, Michael
AU  - Bohm M
FAU - Dei Cas, Livio
AU  - Dei Cas L
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20111206
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Benzopyrans)
RN  - 0 (Ethanolamines)
RN  - 030Y90569U (Nebivolol)
SB  - IM
MH  - Adrenergic beta-Antagonists/*pharmacology/therapeutic use
MH  - Aged
MH  - Benzopyrans/*pharmacology/therapeutic use
MH  - Diastole
MH  - Double-Blind Method
MH  - Ethanolamines/*pharmacology/therapeutic use
MH  - Exercise Test/drug effects
MH  - Exercise Tolerance/*drug effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nebivolol
MH  - Stroke Volume
MH  - Ventricular Dysfunction, Left/*drug therapy
MH  - Ventricular Function, Left/*drug effects
EDAT- 2011/12/08 06:00
MHDA- 2012/05/24 06:00
CRDT- 2011/12/08 06:00
PHST- 2011/12/08 06:00 [entrez]
PHST- 2011/12/08 06:00 [pubmed]
PHST- 2012/05/24 06:00 [medline]
AID - hfr161 [pii]
AID - 10.1093/eurjhf/hfr161 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2012 Feb;14(2):219-25. doi: 10.1093/eurjhf/hfr161. Epub 2011 
      Dec 6.